Impact of genomic studies on pediatric solid cancers at diagnosis
Evaluation of the Clinical and Therapeutic Impact of Large Genomic Studies at Diagnosis in Pediatric Solid Cancers
University Hospital, Strasbourg, France · NCT06171971
This study is testing how using genetic information from tumors at diagnosis can help doctors create better treatment plans for children and young adults with tough-to-treat solid cancers.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 230 (estimated) |
| Ages | 1 Year to 22 Years |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France (other) |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT06171971 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the clinical and therapeutic impact of large genomic studies conducted at the time of diagnosis in pediatric patients with solid tumors. It focuses on children and young adults up to 22 years old who have been diagnosed with solid tumors that have an unfavorable prognosis. The study will analyze molecular data from tumor or blood samples to inform personalized treatment approaches. The goal is to improve understanding and management of these challenging cancers, which currently have low survival rates.
Who should consider this trial
Good fit: Ideal candidates for this study are pediatric patients up to 22 years old with a histologically confirmed diagnosis of solid tumors that are refractory or in relapse.
Not a fit: Patients whose molecular biology results are unusable due to poor sample quality or insufficient genetic material may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for pediatric patients with solid tumors.
How similar studies have performed: While genomic studies have shown promise in adult populations, this approach in pediatric solid tumors is still under consideration and represents a novel effort.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria * Patients of pediatric age up to 22 years included at the time of molecular analysis * Histological carcinological diagnosis performed at HUS * Carcinological follow-up performed at HUS * Patients with a solid tumor of unfavorable prognosis, refractory or in relapse * Molecular analysis performed on tumor or blood samples * Adult patients who do not object to the re-use of their personal data for medical research purposes * Minor patients and their parents who do not object to the re-use of their personal data for scientific research purposes. Criteria for non-inclusion * Molecular biology results not usable due to poor sample quality or insufficient genetic material * Patients who have expressed their opposition to participate in the study * Parental authority holders who have expressed their opposition to participate in the study
Where this trial is running
Strasbourg
- Service d'onco-hématologie pédiatrique - CHU de Strasbourg - France — Strasbourg, France (RECRUITING)
Study contacts
- Study coordinator: Natacha ENTZ-WERLE, MD, PhD
- Email: natacha.entz-werle@chru-strasbourg.fr
- Phone: 33 3.88.12.87.94
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pediatric Solid Tumors, Pediatric solid tumors, BROAD GENOMIC STUDIES, SOLID CANCERS, Genomic medicine